

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/563,682	01/06/2006	Mark T. Gladwin	4239-67618-05	3411
36218	7590 12/12/2007 SDADKMANI LID		EXAMINER	
KLARQUIST SPARKMAN, LLP 121 S.W. SALMON STREET			ARNOLD, ERNST V	
SUITE #1600 PORTLAND	OR 97204-2988		ART UNIT	PAPER NUMBER
			1616	
			MAIL DATE	DELIVERY MODE
			12/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	- Applicant(s)				
	10/563,682	GLADWIN ET AL.				
Office Action Summary	Examiner	Art Unit ·				
<u>-</u>	Ernst V. Arnold	1616				
The MAILING DATE of this communication app						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	TE OF THIS COMMUNICATION (6(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on	_•	•				
2a) ☐ This action is FINAL . 2b) ☒ This	This action is FINAL . 2b)⊠ This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	63 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1-28 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	election requirement					
8) Claim(s) <u>1-28</u> are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examine		•				
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
	•	•				
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application						
Paper No(s)/Mail Date 6) Other:						

10/563,682 Art Unit: 1616

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Please note that claim 19 is improperly dependent on claim 18 because the hemolytic condition is recited in claim 17. Please correct.

Group I, claim(s) 1-16 and 18 drawn to a method for inducing vasodilation and/or increasing blood flow in a subject, comprising administering to the subject an effective amount of a non-acidified pharmaceutically-acceptable salt of nitrite for a sufficient period of time to induce vasodilation and/or increase blood flow in the subject.

Group II, claim(s) 1-15, 17 and 19, drawn to a method for inducing vasodilation and/or increasing blood flow in a subject, comprising administering to the subject an effective amount of a non-acidified pharmaceutically-acceptable salt of nitrite for a sufficient period of time to induce vasodilation and/or increase blood flow in the subject.

Group III, claim(s) 1-15 and 20-28, drawn to a method for inducing vasodilation and/or increasing blood flow in a subject, comprising administering to the subject an effective amount of a non-acidified pharmaceutically-acceptable salt of nitrite for a sufficient period of time to induce vasodilation and/or increase blood flow in the subject.

10/563,682 Art Unit: 1616

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Claim 1-15 link(s) inventions Group I claims 16 and 18; Group II claims 17 and 19 and Group III claims 20-28. The restriction requirement between the linked inventions is **subject to** the nonallowance of the linking claim(s), claims 1-15. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions **shall** be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 **Claims that require all the limitations of an allowable linking claim** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The concept of increasing blood

10/563,682 Art Unit: 1616

flow by administration of a vasodilator such as sodium nitrite is already taught in the art (See US 4,849,226; title, column 6, lines 53-55 and claim 1). Since the special technical feature is disclosed in the art then Unity of Invention is lacking and restriction is deemed proper.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are drawn to a myriad number of inventions to numerous for the Examiner to elaborate. Depending upon which invention is elected by Applicant, a species election is also required.

- I. The six species of claim 14 do not share a common core structure, have different functional effects and do not render one obvious over the other. Applicant is required to elect a single species for examination.
- II. The fifteen species of claim 18 are drawn to different patient populations with different disorders. Applicant is required to elect a single vascular complication for examination.

10/563,682 Art Unit: 1616

III. The thirty nine species of claim 19 are drawn to wildly different hemolytic conditions (disease states and medical procedures) such as burns, transfusion, cardiopulmonary bypass and malaria. Applicant is required to elect a single hemolytic condition for examination.

IV. The forty six species of claim 21 are drawn to wildly different disease states and medical procedures such as burns, transfusion, cardiopulmonary bypass and malaria. Applicant is required to elect a single species for examination.

V. The seven tissue types of claim 23 are drawn to different tissues with different functions. The Examiner would group neuronal with CNS tissue and bowel with intestinal tissue to create 5 groups of tissue. Applicant is required to elect a single tissue species for examination.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: While the disease state require different patient populations with different treatment regimens and expected outcomes, which differs from the claimed medical procedures such as cardiopulmonary bypass, the instant tissues do not share a common technical feature because they are functionally different and they have been grouped by their different respective functions. Furthermore, the art teaches the differences between them as in: US 5,263,473 discloses methods of increasing blood flow in a patients limb (claim 5); US 4,163,790 discloses methods of increasing coronary arterial blood flow (claim 1); and US 3,865,942 discloses methods of increasing cerebral blood flow (claim 1). The art teaches separate independent claims for methods of inducing vasodilation (US 4,211,782 claims 22 and 33 and US 6,474,037 claim 10 and note claims 19 and 20 recite the addition of a phosphodiesterase inhibitor) and methods for increasing blood flow (US 4,849,226 claim 1)

10/563,682 Art Unit: 1616

A telephone call was made to Tanya Harding on 12/06/07 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

10/563,682 Art Unit: 1616

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ernst V. Arnold whose telephone number is 571-272-8509. The examiner can normally be reached on M-F (6:15 am-3:45 pm).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ernst Arnold
Patent Examiner
Technology Center 1600
Art Unit 1616

/ JOHN PAK PRIMARY EXAMINER

Johann R. Richter
Supervisory Patent Examiner

Technology Center 1600